Skip to content
Cephalexin
Keflet, Keflex, Keftab, Panixine (cephalexin) is a small molecule pharmaceutical. Cephalexin was first approved as Keflet on 1982-01-01. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, escherichia coli infections, and haemophilus infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
wounds and injuriesD014947
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cephalexin
Tradename
Company
Number
Date
Products
KEFLETEli LillyN-050440 DISCN1982-01-01
3 products
KEFLEXPragma PharmaceuticalsN-050405 DISCN1982-01-01
4 products, RLD
KEFLEXPragma PharmaceuticalsN-050406 DISCN1982-01-01
3 products, RLD
Hide discontinued
Cephalexin hydrochloride
Tradename
Company
Number
Date
Products
KEFTABEli LillyN-050614 DISCN1987-10-29
3 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cephalexinANDA2023-06-07
keflexANDA2016-07-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
human bites—D001734W50.3
infectious bone diseases—D001850—
klebsiella infectionsEFO_1001353D007710—
moraxellaceae infectionsEFO_1001072D045828—
otitis mediaEFO_0004992D010033H66.9
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DB: First-generation cephalosporins
— J01DB01: Cefalexin
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEPHALEXIN
INNcefalexin
Description
Cephalexin is a semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract. It has a role as an antibacterial drug. It is a cephalosporin, a semisynthetic derivative and a beta-lactam antibiotic allergen. It is a conjugate acid of a cephalexin(1-).
Classification
Small molecule
Drug classFirst-generation cephalosporin
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1.O
Identifiers
PDB—
CAS-ID15686-71-2
RxCUI1299782
ChEMBL IDCHEMBL1200544
ChEBI ID3535
PubChem CID27447
DrugBankDB00567
UNII ID5SFF1W6677 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 11,031 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details